Recursion Pharmaceuticals (RXRX) Prepaid Assets (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Prepaid Assets came in at $24.2 million in Q1 2026, up 881.62% YoY from $2.5 million in Q1 2025, and down 15.12% on a QoQ basis from $28.6 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Prepaid Assets (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Prepaid Assets data on file, last reported at $24.2 million in Q1 2026.
- Quarterly Prepaid Assets rose 881.62% year-over-year to $24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (up 881.62% YoY) and the FY2025 annual result came in at $28.6 million, down 25.04% from the prior year.
- Prepaid Assets declined to $24.2 million in Q1 2026, from $28.6 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $43.7 million in Q2 2024 to a low of $2.5 million in Q1 2025.
- A 5-year average of $25.0 million and a median of $18.8 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2025 — Prepaid Assets slumped 94.05% — and 2026, when it soared 881.62%.
- Tracing RXRX's Prepaid Assets over 5 years: stood at $15.9 million in 2022, then jumped by 153.62% to $40.2 million in 2023, then decreased by 5.32% to $38.1 million in 2024, then slipped by 25.04% to $28.6 million in 2025, then decreased by 15.12% to $24.2 million in 2026.
- The last three Prepaid Assets figures came in at $24.2 million (Q1 2026), $28.6 million (Q4 2025), and $2.5 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.32 Mn |
| Mar 31, 2026 | 24.25 Mn |
| Dec 31, 2025 | 28.57 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 38.11 Mn |
| Sep 30, 2024 | 42.72 Mn |
| Jun 30, 2024 | 43.73 Mn |
| Mar 31, 2024 | 41.50 Mn |
| Dec 31, 2023 | 40.25 Mn |
| Sep 30, 2023 | 17.78 Mn |
| Jun 30, 2023 | 18.77 Mn |
| Mar 31, 2023 | 15.61 Mn |
| Dec 31, 2022 | 15.87 Mn |
| Sep 30, 2022 | 13.25 Mn |
| Jun 30, 2022 | 16.98 Mn |
| Mar 31, 2022 | 15.43 Mn |
| Dec 31, 2021 | 7.51 Mn |
| Sep 30, 2021 | 9.45 Mn |
| Jun 30, 2021 | 4.62 Mn |
| Mar 31, 2021 | 2.62 Mn |